Dna assay for the prediction of autoimmune diabetes
CA 2246487 A1 · Owner: Mcgill University · Inventors: Grabs, Rosemarie; Polychronakos, Constantin; Vafiadis, Petros
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel DNA assay for the diagnosis and/or prediction of autoimmune diabetes. The present invention relates to a DNA assay for the prediction of autoimmune diabetes in human subjects, which comprises the steps of a) obtaining a DNA sample from the subject and PCR amplification of class III alleles of variable number of tandem repeats (VNTR) located upstream of the insulin gene (INS); and b) electrophoretic co-migration of amplified fragment to identify class III alleles of the insulin VNTR which are identical to S1 or S2, from alleles which differ from S1 and S2; whereby identification of S1 or S2 allele is indicative of at least 1% risk of autoimmune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 3, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 3, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 3, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.